| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4dc9745587fcd926225a68461fe396d7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_18d9c1b0e1da195e2ed591cbf94a12cf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5f992a3096d51f210c239462125a1bac
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_769b6c28a0efd27fe0bd78557affe66d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-467
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-36 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46 |
| filingDate |
2009-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_481bc48925730e4aafb08db39adb18fa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_952b7189903cdae9cc427478254f5858
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ae21e244c5782eb83ccf70b3d9637ad4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7126e5965a0cdccc76bd213b6a77b096 |
| publicationDate |
2009-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2009252726-A1 |
| titleOfInvention |
Antibodies for inhibiting blood coagulation and methods of use thereof |
| abstract |
The invention includes antibodies that provide superior anti-coagulant activity by binding native human TF with high affinity and specificity. Antibodies of the invention can effectively inhibit blood coagulation in vivo. Antibodies of the invention can bind native human TF, either alone or present in a TF:FVIIa complex, effectively preventing factor X or FIX binding to TF or that complex, and thereby reducing blood coagulation. Preferred antibodies of the invention specifically bind a conformational epitope predominant to native human TF, which epitope provides an unexpectedly strong antibody binding site. Also provided are humanized antibodies and fragments thereof that bind to the TF. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009092602-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009136501-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7968094-B2 |
| priorityDate |
2001-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |